I & I, you are one of quite a few pounding the table on AGN with bullish, outperform and exuberant forward looking ratings.
What is the timeline for your target price?
And please elaborate as to whether your analysis covers the recent arrival of Valeant Pharm.(VRX), into a mano-a-mano with AGN in the aesthetic and dermatology sector.
I view this competition as a huge positive and should result in an expansion and build out of the sector over the next 5 to 10 years.
With AGN, being the 800 LB gorilla, it should benefit the most, however; VRX should also benefit and the net result should be a win-win.
Does your attached assessment baked in this scenario?